Risk assessment of venous thromboembolism in medical patientsHARENBERG, J.Seminars in hematology. 2000, Vol 37, Num 3, pp 3-6, issn 0037-1963, SUP5Article

Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexideHARENBERG, J.Medicinal research reviews (Print). 1998, Vol 18, Num 1, pp 1-20, issn 0198-6325Article

Pharmacology of low molecular weight heparinsHARENBERG, J.Seminars in thrombosis and hemostasis. 1990, Vol 16, pp 12-18, issn 0094-6176, 7 p., SUPConference Paper

High-performance size exclusion chromatography and polyacrylamide gel electrophoresis for characterization of unfractionated and low molecular mass glycosaminoglycansMALSCH, R; HARENBERG, J.Seminars in thrombosis and hemostasis. 1994, Vol 20, Num 2, pp 135-143, issn 0094-6176Conference Paper

UROKINASE-BEHANDLUNG DER PHLEGMASIA COERULEA DOLENS = TRAITEMENT PAR L'UROKINASE DE PHLEGMATIA COERULEA DOLENSZIMMERMANN R; MORL H; HARENBERG J et al.1979; DTSCHE MED. WSCHR.; DEU; DA. 1979; VOL. 104; NO 44; PP. 1563-1567; ABS. ENG; BIBL. 32 REF.Article

FIBRINOPEPTIDE A IN HUMAN PLASMA-EVALUATION OF A NEW RADIOIMMUNOASSAY TECHNIQUE ON MICROLITER-PLATESHARENBERG J; HEPP G; SCHMIDT GAYK et al.1979; THROMBOSIS RES.; GBR; DA. 1979; VOL. 15; NO 3-4; PP. 513-522; BIBL. 8 REF.Article

MEASUREMENT OF FIBRINOPEPTIDE A IN PATIENTS TREATED WITH PHENOPROCOUMONHARENBERG J; HAAS R; ZIMMERMANN R et al.1981; THROMB. HAEMOST.; ISSN 0340-6245; DEU; DA. 1981; VOL. 45; NO 3; PP. 282-284; BIBL. 21 REF.Article

UROKINASE THERAPY: DOSE REDUCTION BY ADMINISTRATION IN PLASTIC MATERIALZIMMERMANN R; SCHOEFFEL G; HARENBERG J et al.1981; THROMB. HAEMOST.; ISSN 0340-6245; DEU; DA. 1981; VOL. 45; NO 3; PP. 296; BIBL. 4 REF.Article

Lipolytic activities of low molecular weight heparinsHARENBERG, J; AUGUSTIN, J.Thrombosis research. 1986, Vol 42, Num 6, pp 865-866, issn 0049-3848Article

IS THE DIURNAL INCREASE OF FIBRINOLYTIC ACTIVITY INFLUENCED BY ALPHA- OR BETA-ADRENERGIC BLOCKADE.HARENBERG J; WEBER E; SPOHR U et al.1980; BLUT; ISSN 0006-5242; DEU; DA. 1980; VOL. 41; NO 6; PP. 455-458; ABS. GER; BIBL. 11 REF.Article

Characterization of heparins by high-performance size exclusion liquid chromatographyHARENBERG, J; DE VRIES, J. X.Journal of chromatography. 1983, Vol 261, Num 2, pp 287-292, issn 0021-9673Article

Pharmacology and special clinical applications of low-molecular-weight heparinsHARENBERG, J; HEENE, D. L.American journal of hematology. 1988, Vol 29, Num 4, pp 233-240, issn 0361-8609Article

BLOOD COAGULATION CHANGES DURING EFFECTIVE THROMBOLYSIS USING UROKINASE AND HEPARINSCHOEFFEL G; ZIMMERMANN R; HARENBERG J et al.1982; THROMB. RES.; ISSN 0049-3848; USA; DA. 1982; VOL. 25; NO 1-2; PP. 11-21; BIBL. 41 REF.Article

Comparison of three heparin bovine serum albumin binding methods for production of antiherapin antibodiesHUHLE, G; HARENBERG, J; MALSCH, R et al.Seminars in thrombosis and hemostasis. 1994, Vol 20, Num 2, pp 193-204, issn 0094-6176Conference Paper

LACK OF EFFECT OF CIMETIDINE ON ACTION OF PHENPROCOUMONHARENBERG J; ZIMMERMANN R; STAIGER C et al.1982; EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY; ISSN 0031-6970; DEU; DA. 1982; VOL. 23; NO 4; PP. 365-367; BIBL. 21 REF.Article

EVALUATION OF SMOKING-INDUCED EFFECTS ON SYMPATHETIC, HEMODYNAMIC AND METABOLIC VARIABLES WITH RESPECT TO PLASMA NICOTINE AND COHB LEVELSSPOHR U; HOFMANN K; STECK W et al.1979; ATHEROSCLEROSIS; NLD; DA. 1979; VOL. 33; NO 3; PP. 271-283; BIBL. 29 REF.Article

ACUTE CARDIOVASCULAR REACTIONS AFTER CIGARETTE SMOKINGKOCH A; KOFFMANN K; STECK W et al.1980; ATHEROSCLEROSIS; NLD; DA. 1980; VOL. 35; NO 1; PP. 67-75; BIBL. 15 REF.Article

Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PICT methodFENYVESI, T; JÖRG, I; HARENBERG, J et al.Pathophysiology of haemostasis and thrombosis (Print). 2002, Vol 32, Num 4, pp 174-179, issn 1424-8832, 6 p.Article

Gas-liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfatesALBAN, S; FRANZ, G.Seminars in thrombosis and hemostasis. 1994, Vol 20, Num 2, pp 152-158, issn 0094-6176Conference Paper

Comparative human pharmacology of low molecular weight heparinsHARENBERG, J; STEHLE, G; AUGUSTIN, J et al.Seminars in thrombosis and hemostasis. 1989, Vol 15, Num 4, pp 414-423, issn 0094-6176Article

Niedermolekulare Heparine : Prophylaxe und Therapie thromboembolischer Erkrankungen = Low-molecular-weightheparins intheprophylaxis and treatment of thromboembolic diseasesHARENBERG, J; HUHLE, G; PIAZOLO, L et al.Hautarzt. 1997, Vol 48, Num 11, pp 852-864, issn 0017-8470Article

Zur Plazentagängigkeit von niedermolekularem Heparin = Placental passage of low molecular heeeparinSCHNEIDER, D; HEILMANN, L; HARENBERG, J et al.Geburtshilfe und Frauenheilkunde. 1995, Vol 55, Num 2, pp 93-98, issn 0016-5751Article

Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with R-hirudinXUEHONG SONG; HUHLE, G; LIANCHUN WANG et al.Circulation (New York, N.Y.). 1999, Vol 100, Num 14, pp 1528-1532, issn 0009-7322Article

High-resolution capillary electrophoresis and polyacrylamide gel electrophoresis of heparinsMALSCH, R; HARENBERG, J; HEENE, D. L et al.Journal of chromatography. A. 1995, Vol 716, Num 1-2, pp 259-268Conference Paper

Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatientsHARENBERG, J; ROEBRUCK, P; HEENE, D. L et al.Haemostasis. 1996, Vol 26, Num 3, pp 127-139, issn 0301-0147Article